Metraipolis › archive › dc_8334282bfc66

Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis — Europe PMC PMID:40511660

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40511660
DOI
10.2174/011573403x357542250526072430
License (as archived)
solo-consultazione
Archived
2026-11-07T05:52:02.749Z
SHA-256 of the archived text
b7881de2c9c4a01dc6e1faeea3a339dd2d02a85407aa1256e5f70edef84f1525
Stable URL of this page
https://metraipolis.com/documento/dc_8334282bfc66

How to cite

Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis — Europe PMC PMID:40511660 — Europe PMC (en), https://europepmc.org/article/MED/40511660 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8334282bfc66 (Metraipolis archive dc_8334282bfc66, sha256 b7881de2c9c4a01dc6e1faeea3a339dd2d02a85407aa1256e5f70edef84f1525)
BibTeX
@misc{dc8334282bfc66,
  title = {Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis — Europe PMC PMID:40511660},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40511660},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8334282bfc66; sha256 b7881de2c9c4a01dc6e1faeea3a339dd2d02a85407aa1256e5f70edef84f1525},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40511660. Agents can read the archived copy with the MCP tool read_document.